...market. On Monday, AstraZeneca plc (LSE:AZN; NYSE:AZN) reported that its cancer immunotherapies Imfinzi durvalumab and tremelimumab...
...approved to treat locally advanced or metastatic urothelial cancer and unresectable stage III NSCLC, while tremelimumab...
...Programmed cell death 1 ligand 1 Erin McCallister, Senior Editor Imfinzi, durvalumab (MEDI4736) tremelimumab (CP-675, CP-675,206, CP-675206, ticilimumab) Keytruda...

...AstraZeneca announced Wednesday that its Imfinzi durvalumab/tremelimumab combination failed to show a survival benefit in first-line...
...tremelimumab also missed primary endpoints in NSCLC patients in the MYSTIC and ARCTIC trials (see "Imfinzi-Tremelimumab...
...Programmed cell death 1 ligand 1 Erin McCallister, Senior Editor Imfinzi, durvalumab (MEDI4736) tremelimumab (CP-675, CP-675,206, CP-675206, ticilimumab) AstraZeneca AstraZeneca...

...nanoparticle. The trial is testing mRNA-2752 as monotherapy or in combination with Imfinzi durvalumab or tremelimumab...

...that AZ removed from its pipeline two Phase III programs evaluating Imfinzi plus CTLA-4 inhibitor tremelimumab...
...lists 17 Phase III and Phase II trials of this combination in its pipeline (see "Imfinzi-Tremelimumab...

...modified human IL-36γ, IL-23 and OX40L - alone or in combination with Imfinzi durvalumab or tremelimumab...

...lipid nanoparticle. Moderna is testing mRNA-2752 as monotherapy or in combination with Imfinzi durvalumab or tremelimumab...
...with melanoma resistant to checkpoint inhibitors. Imfinzi is a human IgG1 mAb targeting PD-L1 and tremelimumab...
...CTLA-4 (CTLA4; CD152) - Cytotoxic T-lymphocyte associated protein 4 Sandi Wong Imfinzi, durvalumab (MEDI4736) mRNA-2752 tremelimumab (CP-675, CP-675,206, CP-675206, ticilimumab) AstraZeneca...

...setbacks during Bohen's term, including failures as a part of a combination with CTLA-4 inhibitor tremelimumab...
...Imfinzi as monotherapy to treat advanced NSCLC were unlikely to support a regulatory submission (see "Imfinzi-tremelimumab...
...olaparib (AZD2281, KU-0059436, MK-7339) Tagrisso (Brand), AZD9291 (Compound #), osimertinib (Generic), Tagrisso (Other) tremelimumab (CP-675, CP-675,206, CP-675206, ticilimumab) AstraZeneca...

...setbacks during Bohen's term, including failures as a part of a combination with CTLA-4 inhibitor tremelimumab...
...Imfinzi as monotherapy to treat advanced NSCLC were unlikely to support a regulatory submission (see "Imfinzi-tremelimumab...
...olaparib (AZD2281, KU-0059436, MK-7339) Tagrisso (Brand), AZD9291 (Compound #), osimertinib (Generic), Tagrisso (Other) tremelimumab (CP-675, CP-675,206, CP-675206, ticilimumab) AstraZeneca...

...In yet another setback for tremelimumab, AstraZeneca plc (LSE:AZN; NYSE:AZN) said the anti-CTLA-4 mAb in combination...
...without tremelimumab to treat SCCHN in patients who have not received prior chemotherapy. AZ in-licensed tremelimumab...
...Status: Phase III data Milestone: Phase III data (1H19) Brian Moy Imfinzi, durvalumab (MEDI4736) tremelimumab (CP-675, CP-675,206, CP-675206, ticilimumab) AstraZeneca...

...In yet another setback for tremelimumab, AstraZeneca plc (LSE:AZN; NYSE:AZN) said the anti-CTLA-4 mAb in combination...
...without tremelimumab to treat SCCHN in patients who have not received prior chemotherapy. AZ in-licensed tremelimumab...
...SCCHN that has progressed on or after platinum-containing chemotherapy. Brian Moy Imfinzi, durvalumab (MEDI4736) tremelimumab (CP-675, CP-675,206, CP-675206, ticilimumab) AstraZeneca...